302 related articles for article (PubMed ID: 30083264)
1. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.
Sanchez-Martinez D; Allende-Vega N; Orecchioni S; Talarico G; Cornillon A; Vo DN; Rene C; Lu ZY; Krzywinska E; Anel A; Galvez EM; Pardo J; Robert B; Martineau P; Hicheri Y; Bertolini F; Cartron G; Villalba M
Theranostics; 2018; 8(14):3856-3869. PubMed ID: 30083264
[TBL] [Abstract][Full Text] [Related]
2. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
4. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
[TBL] [Abstract][Full Text] [Related]
5. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
6. Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.
Weitzman J; Betancur M; Boissel L; Rabinowitz AP; Klein A; Klingemann H
Leuk Lymphoma; 2009 Aug; 50(8):1361-8. PubMed ID: 19562616
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
8. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
Front Immunol; 2019; 10():1943. PubMed ID: 31475004
[TBL] [Abstract][Full Text] [Related]
9. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
10. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity.
Voskens CJ; Watanabe R; Rollins S; Campana D; Hasumi K; Mann DL
J Exp Clin Cancer Res; 2010 Oct; 29(1):134. PubMed ID: 20937115
[TBL] [Abstract][Full Text] [Related]
11. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.
García-Muñoz R; Aguinaga L; Feliu J; Anton-Remirez J; Jorge-Del-Val L; Casajús-Navasal A; Nebot-Villacampa MJ; Daroca-Fernandez I; Domínguez-Garrido E; Rabasa P; Panizo C
Immunotherapy; 2018 Mar; 10(6):491-499. PubMed ID: 29562857
[TBL] [Abstract][Full Text] [Related]
13. From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement.
Coënon L; Villalba M
Front Immunol; 2022; 13():913215. PubMed ID: 35720368
[TBL] [Abstract][Full Text] [Related]
14. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
16. HLA-C matching status does not affect rituximab-mediated antibody-dependent cellular cytotoxicity by allogeneic natural killer Cells.
Machino T; Okoshi Y; Miyake Y; Akatsuka Y; Chiba S
Immunol Invest; 2012; 41(8):831-46. PubMed ID: 22676066
[TBL] [Abstract][Full Text] [Related]
17. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
18. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
19. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
Awan FT; Lapalombella R; Trotta R; Butchar JP; Yu B; Benson DM; Roda JM; Cheney C; Mo X; Lehman A; Jones J; Flynn J; Jarjoura D; Desjarlais JR; Tridandapani S; Caligiuri MA; Muthusamy N; Byrd JC
Blood; 2010 Feb; 115(6):1204-13. PubMed ID: 19965644
[TBL] [Abstract][Full Text] [Related]
20. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]